US Investigational New Drug (IND) Application — Summary — GLPI-103
📚 Part of the GLPI-103 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.
This is a mock / simulation document, made for a portfolio and for learning. The drug (GLPI-103), the sponsor, the people, and the data are all fictional. It is not a real regulatory submission and has no clinical, legal, or regulatory standing. What is real is the shape of the thing — the document structure, the standards it follows, and the analysis methods; the content inside is illustrative.
What it is. A summary of the US Investigational New Drug (IND) application — the package a sponsor files with the FDA before dosing humans in the US.
Why it exists. In the US you may not ship an investigational drug across state lines or dose subjects until an IND is in effect. It bundles the protocol, the Investigator's Brochure, and the manufacturing and pharmacology/toxicology information the FDA reviews for safety before trials begin.
How it is produced here. This is a region-specific administrative document, assembled to the local filing and labeling conventions. Its operational and label content is written to stay consistent with the (simulated) clinical data.
Format & governing standard. 21 CFR 312
US Investigational New Drug (IND) Application — Summary — GLPI-103
In the US you cannot dose humans or ship an investigational drug across state lines until an IND is 'in effect'. The FDA has 30 days to object; if it doesn't, the trial may start. This summary is the sponsor's side of that gate.
| Field | Value |
|---|---|
| Document ID | IND-US |
| Version | 1.0 |
| Region | FDA (US) |
| Standard | 21 CFR 312 |
| Confidentiality | Confidential — portfolio use |
The IND precedes the NDA and authorizes US clinical trials.
[MOCK]administrative identifiers. Cross-references existing modules.
Change History
| Version | Date | Author | Summary |
|---|---|---|---|
| 1.0 | 2026-06-29 | Regulatory (US) | Initial IND summary |
Contents (21 CFR 312.23)
- Form FDA 1571 (cover) and 1572 (investigator statement) — administrative
[MOCK]. - Introductory statement & general investigational plan: GLPI-103 (GLP-1/APJ dual agonist) for T2DM; planned Phase 1→3 program (REF-002).
- Investigator's Brochure: IB-001.
- Clinical protocol(s): initial FIH protocol (→ GLPI103-101); pivotal protocol PROT-301.
- Chemistry, Manufacturing, and Controls (CMC): per Module 3 (M3) — drug substance/product, controls, stability.
- Pharmacology/Toxicology: nonclinical summary supporting first-in-human dosing (M2.4/M2.6; M4 study reports).
- Previous human experience: none at initial IND (first-in-human).
Safety Reporting
Once trials are running, certain serious and unexpected events must be reported to the FDA on strict deadlines (as fast as 7 or 15 days). This section is where those obligations are set out.
IND safety reports (7/15-day) per 21 CFR 312.32; annual reports; aligned with the Safety Management Plan (TMF-SMP).
Comments (0)
No comments yet. Be the first to say something!